Inhibrx Biosciences is trading at $80.02, up 10.89%, amid biotech sector strength. - Biotech (XBI) is up 2.13% as investors rotate away from technology. - Biotech also outperformed broader markets in the prior week. - No major Inhibrx-specific announcement explaining the November 3 move was identified; sector strength supports the direction but does not account for the full gain.